Results 111 to 120 of about 6,620 (168)

Exploiting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Rationale and Evidence for Combining Metabolic Modulators with Conventional Chemotherapy. [PDF]

Pharmaceuticals (Basel)
Shams UA, Inayat F, Zeb MA, Maryam, Shams S, Ullah MJ, Jiménez-Morales S.   +6 more
europepmc   +1 more source

Multichiral Half-Sandwich Ru(II) and Os(II) Anticancer Complexes Containing a Glutathione Synthesis Inhibitor. [PDF]

Organometallics
Kumari P, Bridgewater HE, Anisi S, Whitehouse CM, Millett AJ, Chellan P, Romero-Canelón I, Clarkson GJ, Schünemann V, Wolny JA, Sadler PJ.   +10 more
europepmc   +1 more source

Persistent Monocytic Bioenergetic Impairment and Mitochondrial DNA Damage in PASC Patients with Cardiovascular Complications. [PDF]

Int J Mol Sci
Semo D, Shomanova Z, Sindermann J, Mohr M, Evers G, Motloch LJ, Reinecke H, Godfrey R, Pistulli R.   +8 more
europepmc   +1 more source

Noninvasive in vivo discrimination between mitochondrial ROS and global ROS production in solid tumors using EPR spectroscopy. [PDF]

Redox Biol
Mathieu B, Rondeau JD, Mignion L, Sonveaux P, Gallez B.   +4 more
europepmc   +1 more source

Acute Acetaminophen Hepatotoxicity And Platelet Dysfunction. [PDF]

J Med Toxicol
Ekaney ML, Pritt TA, Attal N, Murphy CM, McKillop IH.   +4 more
europepmc   +1 more source

70 Years of DON and Beyond: Glutaminase Inhibition as a Synergistic Strategy in Cancer Combination Therapy. [PDF]

Pharmaceutics
Campos-Sandoval JA, De Los Santos-Jiménez J, Márquez J, Matés JM.   +3 more
europepmc   +1 more source

A study on enhancement of hyperthermotherapy : in the presence of buthionine sulfoximine (BSO)

, 1991
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacodynamics of Prolonged Treatment With L,S-Buthionine Sulfoximine

International Journal of Radiation Oncology Biology Physics, 1994
To develop dosing criteria for the use of L-buthionine-S-sulfoximine (active diastereoisomer) as a glutathione depletor in the clinic, using a pharmacodynamic and pharmacokinetic in vitro-in vivo approach.In vitro: L-buthionine-S-sulfoximine uptake was determined in human glioblastoma cells (T98G) and NIH-3T3 cells using 35S-labeled drug. Dose response
C Coleman, C N Coleman, Edward A Bump
exaly   +3 more sources

Chemosensitization by buthionine sulfoximine in vivo

International Journal of Radiation Oncology*Biology*Physics, 1986
The in vivo effects of buthionine sulfoximine (BSO), an inhibitor of glutathione (GSH) biosynthesis, on the cytotoxicity of cyclophosphamide (CYM), cisplatin (CDDP) and bleomycin (BLM), were examined by monitoring the changes of non-protein thiols (NPSH) in normal tissues and in the NFSa fibrosarcoma. We used the lung colony assay as a measure of tumor
K, Tsutsui, C, Komuro, K, Ono, T, Nishidai, Y, Shibamoto, M, Takahashi, M, Abe   +6 more
openaire   +2 more sources